Julie Zuniga
Family · El Paso, TXNPI 1124262381
Payments from drug & device makers
Across 327 payments — averaging $31.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- AbbVie$998
- AstraZeneca$715
- Amgen$707
- Lilly USA, LLC$700
- Johnson & Johnson$527
- plus $5K from 32 others
What the payments were for
- Travel & lodging$6126%
- Food & beverage$9,58694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 26 | $1,970 |
| AbbVie | 46 | $998 |
| AstraZeneca(2 entities) | 13 | $715 |
| Amgen | 21 | $707 |
| Lilly USA, LLC | 34 | $700 |
| Johnson & Johnson | 18 | $527 |
| Bayer | 20 | $447 |
| Pfizer | 26 | $422 |
| Novo Nordisk | 12 | $414 |
| Boston Scientific | 4 | $358 |
| Amarin Pharma, Inc. | 16 | $319 |
| GSK | 7 | $255 |
| Mayne Pharma Commercial LLC | 1 | $240 |
| Boehringer Ingelheim | 9 | $233 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $217 |
| Novartis | 10 | $213 |
| Abbott | 10 | $210 |
| Abiomed | 2 | $123 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 3 | $122 |
| Shield Therapeutics Inc | 1 | $107 |
| Medtronic | 1 | $106 |
| Exact Sciences | 6 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Genentech USA, Inc. | 6 | $83 |
| Astellas Pharma US Inc | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Theratechnologies Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Inogen, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Biogen | 1 | $15 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,198 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 216 | $318,304 |
| MounjaroTirzepatide | 114 | $149,227 |
| EliquisApixaban | 110 | $144,641 |
| JanuviaSitagliptin Phosphate | 99 | $116,020 |
| FarxigaDapagliflozin Propanediol | 88 | $98,568 |
| JardianceEmpagliflozin | 66 | $92,472 |
| TrulicityDulaglutide | 58 | $80,855 |
| RybelsusSemaglutide | 56 | $65,498 |
| XareltoRivaroxaban | 43 | $53,505 |
| MyrbetriqMirabegron | 42 | $37,080 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $26,784 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,493 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $14,586 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $14,180 |
| Mirabegron ErMirabegron | 20 | $11,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $414 | $383,802272 claims |
| Lilly USA, LLCMounjaro, Trulicity | $700 | $230,082172 claims |
| PfizerEliquis | $422 | $144,641110 claims |
| MerckJanuvia | $35 | $116,02099 claims |
| AstraZenecaFarxiga, Symbicort | $715 | $104,318105 claims |
| Boehringer IngelheimJardiance | $233 | $92,47266 claims |
| Johnson & JohnsonXarelto | $527 | $53,50543 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $255 | $49,09260 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $37,08042 claims |
| AbbVieSynthroid | $998 | $6,139127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in El Paso
- Margarita FavelaEl Paso$73K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.